Skip to main content
. 2018 Jun 20;16(3):3303–3318. doi: 10.3892/ol.2018.8995

Table I.

The main characteristics of eligible studies in the systematic meta-analysis.

Study population characteristics Experimental method Data
First author, year miR Trend Country Casesa Controlsa Sample type RNA extraction reagent/kit Normalization control RT-qPCR type Cutoff TP FP FN TN (Refs.)
Ye et al, 2014 miR-21 Up China 100 (80/20), 59 (43–88) 50 Plasma mirVANA PARIS miR-16 SYBR YI 97 22 3 28 (52)
Li et al, 2015 miR-21 Up China 24b (18/6), 68.5 (47–87) 19 Plasma mirVANA PARIS miR-1228 TaqMan 3.89 22 6 2 13 (53)
Li et al, 2015 miR-21 Up China 38 (30/8) 19 Plasma mirVANA PARIS miR-1228 TaqMan YI 35 8 3 11 (22)
Wang and Zhang, 2012 miR-21 Up China 31c (23/8), 61 (46–82) 39 (30/9), 46 (−) Plasma Trizol LS miR-16 SYBR 3.37 22 12 9 27 (40)
Komatsu et al, 2011 miR-21 Up Japan 50 (44/6) 20 Plasma mirVANA PARIS Standard curve TaqMan 0.22 24 3 26 17 (23)
Wu et al, 2014 miR-223 Up China 63 (55/8), (62.0±8.3) 63 (55/8), (59.7±6.8) Serum Trizol let-7d, 7g and 7i TaqMan YI 40 12 23 51 (46)
Zhang et al, 2012 miR-223 Up China 113 (88/25) 67 Serum Phenol/ chloroform Standard curve TaqMan 0.71 79 13 34 54 (36)
Zhang et al, 2010 miR-223 Up China 149 (116/33) 100 (74/26) Serum Trizol Serum volume TaqMan YI 124 17 25 83 (39)
Komatsu et al, 2011 miR-375 Down Japan 50 (44/6) 20 Plasma mirVANA PARIS Standard curve TaqMan <0.01 39 5 11 15 (23)
Li et al, 2015 miR-375 Up China 38 (30/8) 19 Plasma mirVANA PARIS miR-1228 TaqMan YI 31 3 7 16 (22)
Wu et al, 2014 miR-25 Up China 63 (55/8), (62.0±8.3) 63 (55/8), (59.7±6.8) Serum Trizol let-7d, 7g and 7i TaqMan YI 47 16 16 47 (46)
Komatsu et al, 2014 miR-25 Up Japan 20 50 Plasma mirVANA PARIS Standard curve TaqMan 0.32 17 7 3 43 (45)
Wu et al, 2014 miR-100 Up China 63 (55/8), (62.0±8.3) 63 (55/8), (59.7±6.8) Serum Trizol let-7d, 7g and 7i TaqMan YI 48 22 15 41 (46)
Zhang et al, 2010 miR-100 Up China 149 (116/33) 100 (74/26) Serum Trizol Serum volume TaqMan 0.01 95 19 54 81 (39)
Xie et al, 2013 miR-10b Down China 29b (24/5), (61.3±9.5) 16 (13/3), (57.5±7.1) Plasma mirVANA PARIS miR-16 SYBR 0.56 24 0 5 16 (37)
Xu et al, 2015 miR-10b Down China 50 (27/23) 50 (30/20) Serum mirVANA PARIS RUN6B TaqMan YI 38 8 12 42 (49)
Zhang et al, 2011 miR-31 Up China 120 (79/41) 81 (49/32) 121 (76/45) 81 (43/38) Serum miRNeasy Mini miR-16 SYBR 0.01 0.01 104 70 19 17 16 11 102 64 (34)
Zhang et al, 2013 miR-1322 Up China 120 (79/41) 81 (49/32) 120 (75/45) 81 (43/38) Serum miRNeasy Mini miR-16 SYBR 0.01 0.01 98 68 21 16 22 13 99 65 (44)
Takeshita et al, 2013 miR-1246 Up Japan 101 (89/12) 46 Serum mirVANA PARIS miR-16 TaqMan 1.32 72 12 29 34 (43)
Zhang et al, 2010 miR-10a Up China 149 (116/33) 100 (74/26) Serum Trizol Serum volume TaqMan YI 121 20 28 80 (39)
Zhang et al, 2010 miR-127 Up China 149 (116/33) 100 (74/26) Serum Trizol Serum volume TaqMan YI 117 13 32 87 (39)
Zhang et al, 2010 miR-133a Up China 149 (116/33) 100 (74/26) Serum Trizol Serum volume TaqMan YI 97 17 52 83 (39)
Zhang et al, 2010 miR-148b Up China 149 (116/33) 100 (74/26) Serum Trizol Serum volume TaqMan YI 99 13 50 87 (39)
Zhang et al, 2010 miR-22 Up China 149 (116/33) 100 (74/26) Serum Trizol Serum volume TaqMan YI 132 14 17 86 (39)
Li et al, 2015 miR-16 Up China 38 (30/8) 19 Plasma mirVANA PARIS miR-1228 TaqMan 3.45 36 8 2 11 (22)
Li et al, 2015 miR-185 Up China 38 (30/8) 19 Plasma mirVANA PARIS miR-1228 TaqMan 3.97 38 8 0 11 (22)
Liu et al, 2012 miR-155 Down China 60, (61.9±7.4) 60, (63.6±8.6) Plasma Trizol RUN6B SYBR YI 38 21 22 39 (35)
Jiang et al, 2015 miR-218 Down China 106b (69/37) 60 Serum mirVANA PARIS miR-16 Molecular beacon 0.77 76 14 30 46 (48)
He et al, 2015 miR-20a Up China 70 (46/24), 40, (61.7±6.9) (60.5±8.4) Plasma Trizol reagent BD TB-126 SV40 SYBR 4.77 45 10 25 30 (47)
He et al, 2015 let-7a Down China 70 (46/24), 40, (61.7±6.9) (60.5±8.4) Plasma Trizol reagent BD TB-126 SV40 SYBR 6.22 52 6 18 34 (47)
Hirajim et al, 2013 miR-18a Up Japan 106 (87/19) 54 Plasma mirVANA PARIS Standard curve TaqMan 1.99 92 0 14 54 (41)
Sharma et al, 2013 miR-107 Down India 14 17 Serum QIAamp Viral RNA mini 5s rRNA SYBR YI 9 3 5 14 (42)
Sun et al, 2015 miR-718 Down China 120 (79/41) 51 Plasma Trizol reagent BD TB-126 miR-16 SYBR 0.09 83 17 37 34 (51)
Guan et al, 2015 miR-613 Down China 75 (43/32) 75 Serum miRNeasy serum/plasma miR-16 SYBR 0.88 61 28 14 47 (50)
Hui et al, 2015 miR-129 Up China 69 14 Serum mirVANA PARIS miR-1228 TaqMan 0.39 54 4 15 10 (38)
Hui et al, 2015 miR-365 Up China 69 14 Serum mirVANA PARIS miR-1228 TaqMan 5.06 56 2 13 12 (38)
Hui et al, 2015 miR-451 Up China 69 14 Serum mirVANA PARIS miR-1228 TaqMan 0.57 57 3 12 11 (38)
Xu et al, 2015 miR-29c Down China 50 (27/23) 50 (30/20) Serum mirVANA PARIS RUN6B TaqMan YI 39 7 11 43 (49)
Xu et al, 2015 miR-205 Down China 50 (27/23) 50 (30/20) Serum mirVANA PARIS RUN6B TaqMan YI 38 7 12 43 (49)
Wu et al, 2014 miR-193 Up China 63 (55/8), (62.0±8.3) 63 (55/8), (59.7±6.8) Serum Trizol let-7d, 7g and 7i TaqMan YI 47 8 16 55 (46)
Wu et al, 2014 miR-194 Up China 63 (55/8), (62.0±8.3) 63 (55/8), (59.7±6.8) Serum Trizol let-7d, 7g and 7i TaqMan YI 54 4 15 10 (46)
Wu et al, 2014 miR-483 Up China 63 (55/8), (62.0±8.3) 63 (55/8), (59.7±6.8) Serum Trizol let-7d, 7g and 7i TaqMan YI 57 3 12 11 (46)
Wu et al, 2014 miR-337 Up China 63 (55/8), (62.0±8.3) 63 (55/8), (59.7±6.8) Serum Trizol let-7d, 7g and 7i TaqMan 0.37 54 4 15 10 (46)
a

Number (males/females) and the mean (± standard deviation) or median (range) age.

b

These studies included esophageal squamous cell carcinoma and esophageal adenocarcinoma histological types.

c

The histological type of the esophageal carcinoma patients was not identified in this study. Ref., reference; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; YI, Youden index; TP, true positive; FP, false positive; FN, false negative, TN, true negative.